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Background-—The mortality rate from cardiovascular disease (CVD) among young adults has declined less than that in the older
population, raising concerns about the increasing prevalence of obesity-related conditions including hypercholesterolemia in the
younger population. We investigated the age-standardized mean levels of serum cholesterols and the prevalence, awareness,
treatment and control rates of hyper-low-density lipoprotein (LDL)-cholesterolemia based on age.
Methods and Results-—Nationally representative samples of 19 489 subjects aged ≥20 years were analyzed from the Korea
National Health and Nutrition Examination Surveys 2008–2010. Hyper-LDL-cholesterolemia was individually evaluated by the 2004
National Cholesterol Education Program Adult Treatment Panel III guidelines. Age-standardized mean levels of total cholesterol,
high-density lipoprotein-cholesterol, LDL-cholesterol, and triglycerides were 186.8, 48.0, 112.9, and 136.0 mg/dL, respectively.
Age-standardized prevalence of hyper-LDL-cholesterolemia was 23.2% (men, 25.5%; women, 21.8%). Among subjects with hyper-
LDL-cholesterolemia, awareness and treatment rates were signiﬁcantly lower in younger adults (<50 years) compared to older
adults ≥50 years (awareness, 8.0% versus 21.5%; treatment, 5.1% versus 18.5%, all Ps<0.001), indicating signiﬁcant discrepancies
in awareness and treatment rates of hypercholesterolemia between younger and older adults. Among subjects aware of their
hyper-LDL-cholesterolemia, younger adults were more likely to have controlled LDL-cholesterol than the elderly (82.1% versus
67.5%, P<0.001).
Conclusions-—Compared to the elderly, signiﬁcant proportions of young and middle-aged adults are unaware of their
hypercholesterolemia and are not treated with proper lipid-lowering medications. Early screening, education, and proper
management should be stressed in national public healthcare policies to reduce the increasing burden of CVD in the younger
population with undiagnosed hypercholesterolemia. ( J Am Heart Assoc. 2014;3:e000650 doi: 10.1161/JAHA.113.000650)
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C ardiovascular disease (CVD) is one of the major leadingcauses of morbidity and mortality worldwide.1,2 A high
level of total cholesterol (TC) and low-density lipoprotein
cholesterol (LDL-C) is recognized as a signiﬁcant contributing
factor to the initiation and progression of atherosclerosis, an
important risk factor for CVD.3,4 Numerous clinical trials have
demonstrated the efﬁcacy and safety of lipid-lowering drugs,
primarily statins, in reducing CVD risk.5–7 However, a large
proportion of adults with high TC and LDL-C still remain
underdiagnosed and undertreated in the United States.4 Data
from the National Health and Nutrition Examination Survey
(NHANES), 2005–2008 shows that 33.5% of adults in the
United States aged ≥20 years have high LDL-C, but only
48.1% of them are treated.8 It has been also reported that
49.1% of the United States population with TC ≥240 mg/dL
are unaware of their condition.9 Based on data from the World
Health Organization Multinational Monitoring of Trends and
Determinants in Cardiovascular Disease (MONICA) project,
the average rate of hypercholesterolemia awareness is only
36% (ranging from 3% [0%] to 62% [65%] in men [women]).10
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Recently, it has become clear that earlier treatment beginning
at age 30 or 35 years can improve the impact of lowering
blood cholesterol level on CVD risk, thanks to advances in our
understanding of the mechanisms regulating blood choles-
terol level and the genes involved in that regulation.11
Therefore, early screening, diagnosis, and treatment of
hypercholesterolemia are important to decrease the incidence
of CVD in high-risk subjects.
The prevalence of hypercholesterolemia varies consider-
ably among population groups.10 Variations in diet, adiposity,
and the use of drugs to lower cholesterol level have led to
differences in serum cholesterol concentrations across pop-
ulations and over time.3 One recent longitudinal study has
clearly demonstrated that CVD mortality is not signiﬁcantly
decreased in young adults compared with older ones over a
time period of 20 years,12 indicating that a large number of
younger adults are not sufﬁciently protected from CVD deaths
in spite of marked developments in pharmacotherapy and
intervention techniques to manage CVD. To date, no study
has yet examined differences in awareness and treatment
rates of hypercholesterolemia between younger and older age
groups. Besides the NHANES data from the United States,
there are few well-conducted national reports on awareness,
treatment and control rates of hypercholesterolemia in the
general population of other countries, especially in Asia.13
Therefore, we analyzed data from the Korea National Health
and Nutrition Examination Survey (KNHANES) conducted in
2008–2010, which was designed by the Ministry of Health
and Welfare to regularly assess the health and nutritional
status of the civilian, non-institutionalized population of
Korea. Hyper-LDL-cholesterolemia was determined after cal-
culating individual risks by the National Cholesterol Education
Program (NCEP) Adult Treatment Panel III (ATP III) Guide-
lines.14 The aims of this study were (1) to investigate the
levels of serum cholesterols and the prevalence, awareness,
treatment, and control of subjects with high LDL-C and (2) to
examine differences in awareness, treatment and control
rates between age groups in the general Korean population.
Methods
Study Participants
Data for this current study were derived from the KNHANES
conducted in 2008–2010. The KNHANES is a nationwide
cross-sectional study regularly conducted by the Division of
Chronic Disease Surveillance, Korea Centers for Disease
Control and Prevention of the Ministry of Health and Welfare
to assess the general health and nutrition status of the civilian,
non-institutionalized population of Korea.15 The KNHANES
includes 4 surveys: a health interview survey, a health behavior
survey, a health examination survey, and a nutrition survey.16
A total of 29 235 individuals participated in the KNHANES
2008–2010 (Figure 1). Among these participants, we excluded
individuals who were aged <20 years (n=7664) and whose lipid
proﬁles were not assessed in the survey (n=2082). Finally, a
total of 19 489 subjects (8382 men and 11 107 women) were
analyzed. Written informed consent was secured from all
participants and KNHANES was conducted based on ethical
approval by Institutional Review Board of Korea Center for
Disease Control and Prevention (No: 2008-04EXP-01-C, 2009-
01CON-03-2C, 2010-02CON-21-C).
Measurements of Anthropometric and Laboratory
Parameters
Blood samples collected from each subject during the survey
were processed, refrigerated immediately, transported in cold
storage to the central laboratory (NeodinMedical Institute, Seoul,
Korea) and analyzed within 24 hours after transportation.17 TC,
high-density lipoprotein cholesterol (HDL-C), triglycerides (TG)
and fasting glucose levels were determined using a Hitachi 7600
automated chemistry analyzer (Hitachi, Tokyo, Japan). LDL-C was
calculated using the Friedewald formula: [LDL-C (mg/dL)=TC
(mg/dL){HDL-C (mg/dL)+TG (mg/dL)/5}] if the TG level was
low (≤400 mg/dL) and measured directly using the Hitachi 7600
analyzer if the TG level was high (>400 mg/dL).
Body mass index (BMI) was determined as the ratio of
weight to height (kg/m2). Standardized health questionnaires
were used to determine behavior and lifestyle characteristics
including cigarette smoking status (never or past/current).
Blood pressure was measured 3 times on the right arm while
the individual was in a seated position after at least 5 minutes
of rest using a mercury sphygmomanometer (Baumanometer;
W.A. Baum Co.). The ﬁnal blood pressure value was obtained
by averaging the second and third blood pressure readings.
Figure 1. Flow diagram of participant inclusion and exclusion
in the Korea National Health and Nutrition Examination Surveys
2008–2010 (KNHANES IV-2, -3, and V-1).
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Deﬁnitions
We applied the deﬁnition of obesity in the Asian-Paciﬁc region
(BMI ≥25 kg/m2) to categorize participants as obese.18
Diabetes mellitus was deﬁned on the basis of (1) insulin or
oral hypoglycemic agent use or (2) fasting plasma glucose
≥126 mg/dL. Impaired fasting glucose was deﬁned as a
fasting plasma glucose of 100 to 125 mg/dL.19 Subjects
were diagnosed as hypertensive if systolic pressure was
≥140 mm Hg, if diastolic pressure was ≥90 mm Hg, or if
current antihypertensive medication was used, according to
standards based on the Seventh Report of the Joint National
Committee on Prevention, Detection, Evaluation, and Treat-
ment of High Blood Pressure (JNC 7).20 Hyper-LDL-cholester-
olemia was deﬁned based on the individual’s LDL-C goals
recommend by the 2004 update of the ATP III guidelines.14 In
addition, all participants who currently reported using cho-
lesterol-lowering agents were considered to have high LDL-C.
Awareness and treatment of hyper-LDL-cholesterolemia were
examined in the health interview survey by self-report.
Subjects who answered, “yes” to the question “Do you
currently have high cholesterol or have you heard from
medical personnel that your blood cholesterol level was
high?” were considered aware of their high cholesterol.
Subjects who reported “yes” to the question “Are you
currently using cholesterol-lowering medication?” were con-
sidered to be receiving treatment. Control of hyper-LDL-
cholesterolemia was deﬁned based on the individual LDL-C
goals suggested by the 2004 update of the ATP III
guidelines14 after evaluation of their cardiovascular risks
(Table 1).
Statistical Analysis
The standardized prevalence, awareness, and treatment rates
were calculated for sex and age, speciﬁc to the Korean
population, as provided by the Ofﬁce for National Statistics in
2010 to adjust and reﬂect the age structure of the 2010 general
population in Korea. We also applied the stratiﬁcation variables
and sampling weights for all analyses designated by the Korean
Centers for Disease Control and Prevention, whichwere derived
from the sample design of each survey year.21 Sampling
weights were applied to all calculations to obtain nationally
representative prevalence estimates in Korea. These weights,
which account for the demographic characteristics of certain
areas where participants were sampled, reﬂect the unequal
probabilities of selection of subjects, participant nonresponse,
and poststratiﬁcation. We stratiﬁed our analyses by age, sex,
region, and family income (quartiles). Household income was
calculated according to the monthly equivalized gross house-
hold income (the equivalized gross household income is the
total household income divided by the root of the number of
household members) and categorized into 4 quartiles as low,
lowmiddle, highmiddle, high. Student t test or one-way analysis
of variance with sampling weights was used to compare
variables among genders or age groups. Categorical variables
were compared using Rao-Scott v2 test with sampling weights.
SAS version 9.2 (SAS Institute) and SPSS version 20.0 for
Windows (IBM Corp) were used to analyze the complex
sampling design of KNHANES and results with a P value
<0.05 were considered signiﬁcant.
Results
Characteristics of the General Korean Population
From KNHANES 2008–2010, 19 489 individuals (6529 in
2008, 7089 in 2009, and 5871 in 2010) were included in our
study. Table 2 displays the clinical features of the sample
stratiﬁed by age. In both men and women, subjects aged 30
to 60 years were recruited more heavily than the other age
groups in order to reﬂect the current age distribution in
Korean society. Across all age groups, 31% (26%) men
(women) were hypertensive and 11% (9%) men (women) were
diabetic. More men than women were overweight/obese and
reported a lifetime history of smoking.
Table 1. Criteria for Hyper-LDL-cholesterolemia and LDL-cholesterol Control in subjects as deﬁned by the 2004 National
Cholesterol Education Program Adult Treatment Panel III Guidelines14
Risk Category
Deﬁnition
Hyper-LDL-Cholesterolemia Controlled LDL-C
High risk: CHD* or CHD risk equivalents† LDL-C ≥100 mg/dL (70 mg/dL‡) or use of lipid-lowering medications LDL-C <100 mg/dL (70 mg/dL‡)
Moderate risk: CHD risk factors§ ≥2 LDL-C ≥130 mg/dL or use of lipid-lowering medications LDL-C <130 mg/dL
Low risk: 0 to 1 CHD risk factors LDL-C ≥160 mg/dL or use of lipid-lowering medications LDL-C <160 mg/dL
CHD indicates coronary heart disease; LDL-C, low-density lipoprotein cholesterol.
*CHD includes history of myocardial infarction, unstable angina, stable angina.
†CHD risk equivalents include carotid artery disease (stroke), and diabetes.
‡Subjects in the category of very high risk: patients with history of acute myocardial infarction, CHD plus (1) diabetes, (2) severe and poorly controlled risk factors (especially continued
cigarette smoking), (3) multiple CHD risk factors ≥2.
§CHD risk factors include older age (≥55 years for women and ≥45 years for men), current cigarette smoking, hypertension, and low high-density lipoprotein cholesterol (HDL-C <40 mg/dL).
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Age-standardized Mean Serum Levels of Total
Cholesterol and LDL-Cholesterol by Age and
Gender
The age-standardized mean serum concentrations of TC, HDL-
C, LDL-C, and TG were 186.8, 48.0, 112.9, and 136.0 mg/dL,
respectively, in Korean adults aged ≥20 years (Table 3). Mean
TC level was similar between men and women ≥20 years of
age; however, it was signiﬁcantly different across age groups
(Figure 2). Mean serum TC level tended to increase with age up
to 50 years, after which it declined gradually in men. In
contrast, TC level was markedly elevated for women 45 to
55 years old, and they also maintained higher levels compared
with those in men >55 years of age (Figure 2A). This indicates
Table 2. Characteristics of Study Subjects in Korea, 2008–2010
KNHANES 2008–2010
P ValueMale (N=8382) Female (N=11 107)
Age, y 43.90.3 45.80.2 0.965
BMI, kg/m2 24.00.0 23.20.0 <0.001
Waist circumference, cm 84.30.3 78.00.2 <0.001
SBP, mm Hg 117.90.2 113.80.3 <0.001
DBP, mm Hg 77.60.2 72.70.2 <0.001
Age groups (years), N (%)
20 to 29 1029 (12) 1382 (12) <0.406
30 to 39 1675 (20) 2289 (21)
40 to 49 1724 (20) 2186 (20)
50 to 59 1481 (18) 1988 (18)
60 to 69 1399 (17) 1784 (16)
70+ 1074 (13) 1478 (13)
BMI groups, N (%)
Normal (<23 kg/m2) 3208 (39) 5430 (49) <0.001
Overweight (23 to 25 kg/m2) 2182 (26) 2430 (22)
Obese (≥25 kg/m2) 2969 (35) 3201 (29)
Hypertension, N (%) 2582 (31) 2913 (26) <0.001
Diabetes, N (%) 959 (11) 1000 (9) <0.001
Cardiovascular disease, N (%) 212 (3) 196 (2) <0.001
Cerebrovascular disease, N (%) 194 (2) 184 (2) <0.001
Smoking
Current 3567 (31) 637 (6) <0.001
Past 2247 (27) 478 (4)
Never 2568 (42) 9992 (90)
Family income
Low 1532 (19) 2350 (21) <0.001
Low middle 2049 (25) 2736 (25)
High middle 2327 (28) 2911 (27)
High 2351 (28) 2908 (27)
Region
Metropolitan 3644 (44) 4919 (44) 0.518
City 2860 (34) 3746 (34)
Rural 1878 (22) 2442 (22)
Data for continuous variables were expressed as meanSE. BMI indicates body mass index; DBP, diastolic blood pressure; KNHANES, Korea National Health and Nutrition Examination
Surveys; SBP, systolic blood pressure.
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Table 3. Age-speciﬁc and Age-standardized Mean Values of Serum Lipids in Korea, 2008–2010
N*
KNHANES 2008–2010
TC (mg/dL) HDL-C (mg/dL) LDL-C (mg/dL) TG (mg/dL)
Mean SE Mean SE Mean SE Mean SE
Aged 20 years and older 0.496 <0.0001 <0.0001 <0.0001
Total 32 431 033 186.8 0.7 48.0 0.2 112.9 0.6 136.0 2.4
Men 14 776 153 186.2 1.1 45.5 0.3 111.2 1.0 159.0 4.0
Women 17 654 880 187.3 0.9 50.5 0.3 114.6 0.8 113.1 2.1
Aged 30 years and older 0.559 <0.001 <0.001 <0.001
Total 27 529 026 190.4 0.7 47.4 0.2 115.9 0.6 143.2 2.4
Men 12 444 281 189.8 1.0 45.0 0.3 113.9 0.9 168.2 4.1
Women 15 084 745 190.9 0.9 49.8 0.3 117.8 0.8 119.0 2.1
Total <0.001 <0.001 <0.001 <0.001
20 to 29 years 4 902 007 170.3 2.2 50.9 0.8 99.2 2.0 103.1 6.1
30 to 39 years 6 673 138 183.1 1.9 48.5 0.6 110.4 1.7 128.7 6.2
40 to 49 years 6 860 955 190.8 2.0 48.0 0.6 115.4 1.8 146.9 8.2
50 to 59 years 5 740 767 196.3 2.3 47.4 0.7 120.0 2.2 154.0 7.9
60 to 69 years 4 628 894 191.6 2.4 46.2 0.7 117.4 2.2 146.5 6.3
70+ years 3 625 271 193.0 2.7 45.1 0.7 120.0 2.3 142.3 5.7
Men <0.001 <0.001 <0.001 <0.001
20 to 29 years 2 331 871 170.8 3.3 47.7 1.0 99.6 3.0 121.0 10.2
30 to 39 years 3 087 356 189.3 2.8 45.1 0.8 114.6 2.6 161.4 10.5
40 to 49 years 3 181 667 196.0 3.0 45.5 0.9 117.2 2.8 184.6 14.2
50 to 59 years 2 622 319 190.2 3.3 44.8 0.9 112.9 3.3 178.5 13.2
60 to 69 years 2 052 452 183.4 3.5 44.9 1.1 109.7 3.3 152.3 10.5
70+ years 1 500 487 181.0 2.8 44.5 0.8 109.8 2.6 133.7 6.6
Women <0.001 <0.001 <0.001 <0.001
20 to 29 years 2 570 135 169.5 2.8 50.9 0.8 99.2 2.0 83.8 5.6
30 to 39 years 3 585 782 176.5 2.4 52.2 0.8 106.0 2.1 93.6 5.1
40 to 49 years 3 679 289 185.3 2.5 50.7 0.8 113.6 2.2 107.4 5.7
50 to 59 years 3 118 448 202.6 3.1 50.1 0.9 127.0 2.7 129.3 7.1
60 to 69 years 2 576 442 199.0 3.1 47.3 0.9 124.1 2.8 141.2 7.1
70+ years 2 124 784 201.0 2.9 45.6 0.8 126.8 2.6 148.4 6.1
BMI
Men <0.001 <0.001 <0.001 <0.001
Normal (<23 kg/m2) 5 632 240 167.6 2.2 52.8 0.9 97.6 2.1 88.6 3.6
Overweight (23 to 25 kg/m2) 3 798 065 182.0 0.6 46.9 0.2 108.5 0.5 141.9 2.1
Obese (≥25 kg/m2) 5 268 321 194.9 0.8 42.7 0.2 116.8 0.8 193.4 3.4
Women <0.001 <0.001 <0.001 <0.001
Normal (<23 kg/m2) 8 773 860 171.2 1.3 55.9 0.5 100.5 1.1 75.4 1.9
Overweight (23 to 25 kg/m2) 3 852 600 183.6 0.5 51.6 0.2 111.9 0.4 102.0 1.0
Obese (≥25 kg/m2) 4 954 241 196.6 0.8 46.9 0.2 122.1 0.7 142.3 2.1
Continued
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Table 3. Continued
N*
KNHANES 2008–2010
TC (mg/dL) HDL-C (mg/dL) LDL-C (mg/dL) TG (mg/dL)
Mean SE Mean SE Mean SE Mean SE
Hypertension status
Men <0.001 <0.001 0.001 <0.001
Normal 6 701 147 183.4 0.7 45.7 0.2 111.0 0.6 140.2 2.5
Prehypertension 3 819 198 191.5 0.9 45.9 0.3 114.1 0.9 171.4 3.7
Hypertension 4 255 807 190.1 0.9 44.5 0.3 111.1 0.8 191.2 3.9
Women <0.001 <0.001 <0.001 <0.001
Normal 10 454 237 181.1 0.5 51.9 0.2 110.2 0.5 96.2 1.1
Prehypertension 2 812 447 196.6 1.0 49.6 0.3 121.8 0.9 127.3 2.5
Hypertension 4 388 196 199.0 0.9 47.4 0.3 122.7 0.8 149.5 2.1
Diabetes status
Men <0.001 <0.001 <0.001 <0.001
Normal 9 913 431 185.0 0.6 46.0 0.2 111.6 0.5 143.9 2.0
Impaired fasting glucose 3 283 344 195.5 1.1 44.8 0.3 115.3 1.0 195.4 4.5
Diabetes 1 579 377 185.6 1.6 42.4 0.4 107.4 1.4 198.0 6.3
Women <0.001 <0.001 <0.001 <0.001
Normal 13 357 760 184.7 0.5 51.4 0.2 113.0 0.4 102.4 1.0
Impaired fasting glucose 2 709 976 198.7 1.1 48.6 0.3 123.4 1.0 136.5 3.0
Diabetes 1 587 144 198.1 1.6 45.5 0.4 120.2 1.4 169.2 4.5
Family income
Men <0.001 0.892 <0.001 0.518
Low 2 518 044 181.9 1.3 45.5 0.4 107.1 1.2 153.9 4.6
Low middle 3 677 051 185.8 0.9 45.6 0.3 110.8 0.9 158.1 3.2
High middle 4 197 725 186.4 0.9 45.4 0.3 111.4 0.8 159.8 3.5
High 4 141 301 188.4 0.8 45.6 0.2 112.8 0.7 161.0 3.8
Women <0.001 <0.001 <0.001 <0.001
Low 3 548 542 193.6 1.0 48.1 0.3 119.1 0.8 136.4 2.7
Low middle 4 535 130 186.7 0.8 50.4 0.3 114.3 0.7 112.5 1.9
High middle 4 605 368 183.7 0.8 51.2 0.2 111.4 0.7 107.1 1.6
High 4 624 677 183.9 0.9 52.2 0.3 112.3 0.7 98.6 1.5
Region
Men 0.881 0.265 0.855 0.610
Metropolitan 6 984 504 186.0 0.8 45.5 0.2 111.3 0.6 157.5 2.7
City 4 784 729 186.5 0.9 45.4 0.2 111.0 0.8 160.7 3.2
Rural 3 006 919 186.4 1.0 45.9 0.4 110.9 1.0 159.8 4.3
Women <0.001 <0.001 <0.001 <0.001
Metropolitan 8 533 767 185.9 0.7 51.3 0.2 113.1 0.6 109.2 1.5
City 5 676 734 185.3 0.7 51.0 0.2 113.2 0.6 108.5 1.7
Rural 3 444 379 191.0 1.0 48.8 0.3 117.7 0.9 124.2 2.2
BMI indicates body mass index; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; SE, standard error; TC, total cholesterol; TG, triglycerides.
*Weighted numbers of subjects.
DOI: 10.1161/JAHA.113.000650 Journal of the American Heart Association 6
Hypercholesterolemia in Korea Lee et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
that lipid metabolism may be affected by changes in sex
hormones such as estrogen in postmenopausal women.22
Trends in LDL-C (Figure 2B) level by age and gender was similar
with the patterns observed for TC. In men, LDL-C level
increased until the 40s, after which it declined gradually. In
women, LDL-C level increased until the 50s, showing abrupt
elevation between 40s and 50s. This LDL-C elevation between
40s and 50s in women made the higher LDL-C level in women
compared with men after 50s, while men showed higher LDL-C
level than women until 40s. The mean TG level in men
increased until 40s, after that it declined gradually. In contrast,
the mean TG level in women increased continuously and
showed a higher level than men after 70s. The HDL-C level
showed decreasing tendency with increasing age both in men
and women, however the differences among age groups were
smaller than other lipid parameters (Table 3). These age- and
gender-related differences in serum cholesterol levels could be
partly explained by the prevalence of obesity in Korea
(Figure 3). Trends in mean TC and LDL levels between men
and women were comparable to the changes in BMI, waist
circumference, and proportion of subjects with obesity and
overweight by ages and gender. In addition, younger men tended
to have higher consumption of cigarettes and alcohol but less
exercise (data not shown), which might contribute to the
increase in cholesterol levels in men aged between 30s and 40s.
Age-standardized mean levels of TC, LDL-C, and TG were
signiﬁcantly higher in women living in rural Korea compared to
those in urban areas, whereas no signiﬁcant difference was
observed in men based on residence (Table 3). In terms of
economic status, men with higher incomes tended to have
higher TCand LDL-C levels, andwomenwith higher incomeshad
signiﬁcantly lower levels of TC, LDL-C, and TG. Unexpectedly,
subjects with impaired fasting glucose showed higher levels of
TC and LDL-C than diabetic or normal subjects, regardless of
gender. Furthermore, TC, LDL-C, and TG levelswere signiﬁcantly
increased in both prehypertensive and hypertensive subjects
compared with the normotensive population.
Prevalence and Awareness of Hyper-LDL-
Cholesterolemia
The overall age-standardized prevalence of hyper-LDL-choles-
terolemia, determined by individual risk based on the ATP III
guideline was 23.2% (Figure 4A). Particularly, young and
middle-aged adults (<50 years) showed signiﬁcantly lower
prevalence of hyper-LDL-cholesterolemia (3.5% to 18.9%)
compared with older individuals (35.6% to 48.2%). The
prevalence of subjects with high LDL-C increased with age
until the 50s and reached a plateau in men, while it gradually
increased over the entire age range in women (Figure 5A).
Among all subjects with a high LDL-C or those who
reported using cholesterol-lowering medications, the overall
proportion of those who were aware of their hyper-LDL-
cholesterolemia was 13.2% (Figure 4B). The awareness of
high LDL-C was signiﬁcantly low in young and middle-aged
population (aged <50 years, 4.2% to 12%), compared with
individuals aged between 50 and 69 years (24.0% to 24.6%). It
gradually increased with age until 60s (from 4.2% to 24.6%),
whereas signiﬁcantly decreased in the elderly aged
≥70 years. In terms of gender, women were more aware of
their condition than men (Figure 5B, 14.8% versus 11.5%). The
difference of awareness between genders was especially
prominent in ages >40 years.
Treatment and Control of Hyper-LDL-
Cholesterolemia
Figure 6 describes the treatment and control of hyper-LDL-
cholesterolemia stratiﬁed by age. The overall treatment rate
among subjects with high LDL-C was estimated to be 10.2%
(Figure 6A). The distribution of treatment rates across age
showed a similar pattern with that of awareness rates; young
and middle-aged adults (aged 20 to 49 years) had signiﬁ-
cantly lower treatment rates, whereas older subjects
(≥50 years) showed higher rates of treatment (2.4% to 8.5%
versus 12.8% to 22.0%, P<0.001). The treatment rate for the
subjects who were already aware of their condition was much
Figure 2. Trends in age-standardized mean serum lipid levels in
Korean subjects. A, Serum levels of total cholesterol. B, Serum levels
of LDL-cholesterol. Blue line (men); red line (women). LDL indicates
low-density lipoprotein.
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higher (52.3%, Figure 6B). Similarly, among individuals aware
of high LDL-C, young and middle-aged adults were less likely
to be treated for high cholesterol than elderly subjects (19.3%
to 48.9% versus 72.9% to 92.0%, P<0.001). Of all ages, the
treatment rate showed a modest increase in women com-
pared with men except for the ages between 40 and 49
(Figure 7A and 7B).
Among participants who reported using cholesterol-lower-
ing medications, the proportion of subjects who achieved
LDL-C levels below their individual LDL-C goals was 61.7%
(Figure 6D). Contrary to the ﬁndings above, young or middle-
aged adults (<50 years) had signiﬁcantly higher LDL-C control
rates compared with the older population aged ≥50 years (80%
to 84.1% versus 55.6% to 74.2%, P<0.001). Particularly,
younger men aged <50 years were more likely to have their
LDL-C at goal when compared with women (Figure 7D). The
overall average control rate was 7.1% among all subjects
deﬁned as high LDL-C (Figure 6C).
Figure 3. Trends in obesity related parameters and prevalence of obesity in Korean subjects. A, Age-
standardized mean body mass index (BMI) in men and women. Blue line (men); red line (women). *P<0.001 for
comparisons between men and women at each age group. Error bars indicate 95% conﬁdence intervals. B,
Age-standardized mean waist circumference in men and women. Blue line (men); red line (women). *P<0.001
for comparisons between men and women at each age group. Error bars indicate 95% conﬁdence intervals. C,
Prevalence of obesity and overweight subjects in Korean men. Light blue bars (overweight, 23 kg/
m2≤BMI<25 kg/m2); dark blue bars (obesity, BMI ≥25 kg/m2). *P<0.001 for comparisons among age groups.
D, Prevalence of obesity and overweight subjects in Korean women. Light red bars (overweight, 23 kg/
m2≤BMI<25 kg/m2); dark red bars (obesity, BMI ≥25 kg/m2). *P<0.001 for comparisons among age groups.
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Discussion
Under the increasing prevalence of CVD-related risk factors
such as high TC or LDL-C, hypertension and obesity, 1 of
every 3 deaths in the United States is attributable to CVD, and
strikingly, about 20% of CVD deaths occur before the age of
65 years. Similarly, mortality rates from ischemic heart
disease in Korea have increased >3 times during 15 years.23
Figure 4. Prevalence and awareness of high LDL-cholesterol among adults in the KHNANES 2008–2010
stratiﬁed by age. A, Prevalence of hyper-LDL-cholesterolemia. Blue bars (subjects aware of their high LDL-C);
red bars (subjects unaware of their high LDL-C). B, Awareness of hyper-LDL-cholesterolemia. KHNANES
indicates Korea National Health and Nutrition Examination Survey; LDL, low-density lipoprotein.
Figure 5. Prevalence and awareness of high LDL-cholesterol among adults from the KHNANES dataset
stratiﬁed by gender and age. Blue bars (men); red bars (women). A, Prevalence of hyper-LDL-
cholesterolemia. *P<0.001 for comparisons between men and women at each age group. †P<0.001 for
comparisons among different age groups in the same gender. B, Awareness of hyper-LDL-cholesterolemia.
*P<0.001, †P<0.05, and ‡P<0.01 for comparisons between men and women at a certain age group.
§P<0.001 for comparisons among different age groups in the same gender. KHNANES indicates Korea
National Health and Nutrition Examination Survey; LDL, low-density lipoprotein.
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After statins were ﬁrst introduced as a lipid-lowering drug in
the 1980s, the Cholesterol Treatment Trialists’ Collaborators
reported an 20% relative risk reduction with statins for
major vascular events per 38.6 mg/dL (1 mmol/L) decrease
in LDL-C,24 demonstrating the preponderance of evidence of
the beneﬁt of statins on CVD. Although there have been
signiﬁcant advances in the research of the epidemiology of
and preventive medicine for CVD, the burden of public disease
still remains high and may be increasing in the future25 as the
rate of obesity increases, populations age, and physical
activity levels decrease. In the era of statins and the obesity
epidemic, we investigated the prevalence, awareness, treat-
ment, and control of adults with high cholesterol based on age
using a national public health survey dataset in Korea.
To date, not many studies have investigated the preva-
lence, awareness, treatment, and control rates of high blood
cholesterol level in the general population of Asia.13 Our study
population is representative of the general Korean population
as a whole because the KNHANES is an ofﬁcial, nationwide
database that reﬂects the geographic and demographic
differences found in Korea. In general, for Korean adults
≥20 years of age, the age-standardized mean values of TC,
Figure 6. Treatment and control rates of high LDL-cholesterol among adults in the KHNANES 2008–2010
stratiﬁed by age. A, Treatment rates among all individuals with high LDL-C. B, Treatment rates among
individuals aware of their high LDL-C. Blue bars (controlled subjects according to their individual LDL-C
goals); red bars (uncontrolled subjects according to their individual LDL-C goals). C, Control rates among all
individuals with high LDL-C. D, Control rates among individuals treated for their high LDL-C. KHNANES
indicates Korea National Health and Nutrition Examination Survey; LDL, low-density lipoprotein.
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HDL-C, LDL-C, and TG were 186.8, 48.0, 112.9, and
136.0 mg/dL, respectively. Compared with previous data
from the KNHANES 2005,21 the mean levels of TC, HDL-C,
and TG slightly increased (from 183.2, 45.0, and 133.7 mg/
dL in KNHANES 2005), while LDL-C was nearly unchanged
(113.1 mg/dL). This deteriorating trend toward dyslipidemia
may be due to an increase in the prevalence of metabolic
syndrome in Korea.26 Mean levels of LDL-C and TG in Korean
adults were higher when compared with a national dataset of
Chinese adults from 2001, whereas HDL-C was lower (TC,
HDL-C, LDL-C, TG; 186, 51.7, 109.5, 128.1 mg/dL, respec-
tively).13 Although mean TC, HDL-C, and LDL-C values were
Figure 7. Treatment and control rates of high LDL-C among adults in the KHNANES 2008–2010 stratiﬁed
by gender and age. Blue bars (men); red bars (women). A, Treatment rates among all individuals with high
LDL-C. *P<0.001, †P<0.05, and ‡P<0.01 for comparisons between men and women at a certain age group.
§P<0.001 for comparisons among different age groups in the same gender. B, Treatment rates among
individuals aware of their high LDL-C. *P<0.001 for comparison between men and women. †P<0.001
for comparisons among different age groups in the same gender. C, Control rates among all individuals
with high LDL-C. *P<0.001 and †P<0.05 for comparisons between men and women at a certain age group.
P-values for comparisons among different age groups in ‡men and in §women. D, Control rates among
individuals treated for their high LDL-C. *P<0.01 for comparison between men and women at a certain age
group. P-values for comparisons among different age groups in ‡men and in §women. KHNANES indicates
Korea National Health and Nutrition Examination Survey; LDL-C, low-density lipoprotein cholesterol.
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signiﬁcantly lower than those found in United States adults
from the NHANES 2010 (TC, HDL-C, LDL-C; 196, 52.5,
116 mg/dL, respectively),27 the serum TG level was markedly
increased in Korean adults (136 versus 110 mg/dL), indicat-
ing the possible impact of genetic or ethnic effects on lipid
metabolism.
Despite the small number of studies regarding the
prevalence of hypercholesterolemia in the general populations
of Asian countries, the prevalence of hyper-LDL-cholesterol-
emia in Korea was quite similar to that of China, 23.2% in our
survey and 24.8% (LDL-C ≥130 mg/dL) in China.13 However,
the Chinese study did not assess LDL-C levels by individual
risk status, which may overestimate the prevalence of hyper-
LDL-cholesterolemia. In the United States,28 the prevalence of
LDL-C ≥130 mg/dL is 35%, which is signiﬁcantly higher than
in Asian countries.
Our study has several distinguishable features. First, in
younger adults (<50 years), men had signiﬁcantly higher
levels of TC and LDL-C, while women showed markedly
elevated values of TC and LDL-C compared with men when
they became older than 50 years. These ﬁndings are likely to
be associated with the age and gender difference in obesity
prevalence in Korea, suggesting that intensive modiﬁcation in
lifestyles to control body weight should be necessary
especially for younger men (<50 years) and older women
(≥50 years). Second, pharmacotherapy for high LDL-C was
more effective in the young and middle-aged population (30 to
49 years, 82.1%) than in elderly subjects (≥60 years, 61.6%)
with average control rates of 61.7%. This ﬁgure is lower than
that of 69% from the NHANES 2005–2008 conducted in
adults ≥20 years old,8 75% to 77% from the Multi-Ethnic
Study of Atherosclerosis in 2000–2002,29 and 81% from a
national Chinese study with adults 35 to 74 years of age in
2000–2001,13 whereas is higher than that of 56.1% from the
Health Survey for England in 2003.30 Hypercholesterolemia
control rates vary depending on the population and country,
with rates ranging from 18% to 100%.10 Third, the overall
treatment rate for subjects with high LDL-C was 10.2% in
Korea. This rate is markedly lower when we compare the
treatment rate from a United States population that reported
a rate of 48%8 as well as rates of other chronic diseases in
Korea; the treatment rates for hypertension31 and diabetes32
were 66% and 49%, respectively. However, the treatment rate
for subjects who were aware of their high LDL-C was
noticeably increased to 52.3%. Considering the impact of
hypercholesterolemia on the development of CVD, vigorous
efforts are necessary within the public health ﬁeld to provide
proper education and counsel about the screening and
management of hypercholesterolemia to laypersons. Lastly,
awareness and treatment rates of high LDL-C were signiﬁ-
cantly lower in younger adults <50 years old (awareness,
8.0%; treatment, 5.1%) compared with those who were
≥50 years old (21.5%; 18.5%), although the prevalence of
high LDL-C was not high in young or middle-aged adults. This
suggests that there is a large proportion of undiagnosed
subjects who are at high risk for CVD among young or middle-
aged individuals. Based on our ﬁndings, we can assume that,
out of 100 subjects with hyper-LDL-cholesterolemia aged
<50 years, 8 are aware of their condition, 5 are being treated
with cholesterol-lowering agents, and 3 subjects have their
LDL-C levels under control, implying that 97% of young and
middle-aged individuals will remain as potentially high-risk
subjects for CVD.16 Consistent with our results, the study
from the NHANES 2005–2008 reported that the treatment
rate for high LDL-C was 11% in adults aged 20 to 39 years but
48% and 64% in adults aged 40 to 64 years or ≥65 years,
respectively.8
Recent data demonstrates that trends inmortality rates from
CVD among young adults have declined less rapidly than the
rates in the older population over the past 20 years,12 raising
concerns about young adultswith a high risk for CVDdeath. This
unfavorable ﬁnding is a result of an increasing prevalence of
obesity-related conditions such as metabolic syndrome,33
hypertension,34 and hypercholesterolemia5 in the young and
middle-aged population. Although NCEP ATP III guidelines
deﬁne men who are ≥45 years old and women who are at least
≥55 years old as high risk for CVD,14 our data clearly suggest
that more attention should be paid to younger subjects who
may be undiagnosed for hypercholesterolemia in order to
alleviate the increasing trend of CVD among young adults.
The present study has some potential limitations that
should be addressed in future investigations. First, as these
ﬁndings were derived from a cross-sectional study, it is
difﬁcult to conclude that lower rates of awareness and
treatment in young and middle-aged adults can directly lead
to an increase in the incidence of future CVD events.
Subsequent prospective studies are needed to validate this
hypothesis and support our ﬁndings. Second, we could not
perform additional analyses to identify putative reasons for
why the younger age groups had a lower awareness of their
cholesterol condition due to the lack of related information in
the dataset.
The present results demonstrate that signiﬁcant propor-
tions of young and middle-aged adults are unaware of their
hyper-LDL-cholesterolemia and are not treated with proper
lipid-lowering medications. Considering the impact of CVD on
an individual’s quality of life and the public health burden of
the disease, intensive efforts in national public healthcare
policy regarding early screening and education is indispens-
able to decrease potentially high-risk individuals for CVD.
Further research is warranted to conﬁrm the impact of low
awareness and treatment rates in young adults on develop-
ment of CVD and to establish effective screening tools for
identifying individuals with hyper-LDL-cholesterolemia.
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